Affordable Access

deepdyve-link
Publisher Website

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target.

Authors
  • Tsang, Tsun Yee1, 2
  • Wei, Wei1, 2
  • Itamochi, Hiroaki3
  • Tambouret, Rosemary1
  • Birrer, Michael J1, 2
  • 1 Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • 2 Harvard Medical School, Boston, Massachusetts, USA.
  • 3 Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Tottori, Japan. , (Japan)
Type
Published Article
Journal
Oncotarget
Publisher
"Impact Journals, LLC "
Publication Date
Nov 14, 2017
Volume
8
Issue
57
Pages
96482–96495
Identifiers
DOI: 10.18632/oncotarget.19946
PMID: 29228547
Source
Medline
Keywords
License
Unknown

Abstract

Clear cell ovarian cancer (CCOC) is an epithelial ovarian cancer histotype with unique pathologic, biologic and clinical features. Despite its worse prognosis than serous ovarian cancer (SOC), the genomic landscape of CCOC is less well defined. Integrated genomic analysis of CCOC allows the identification of potential therapeutic targets to improve the treatment of this tumor. Using comparative genomic hybridization and gene expression profiling, we have screened 12 CCOC cell lines and 40 tumors to identify 45 amplified and overexpressed genes. Pathways analysis of these genes identified 19 genes with cancer-related functions. Of these, PRKCI is one of the most frequently amplified and overexpressed genes and its expression induced cancer cell proliferation and migration/invasion in vitro as well as tumor growth in vivo. Targeting PRKCI by small molecule inhibitor, sodium aurothiomalate (ATM), significantly reduced the in vivo tumor growth and may be a new therapeutic strategy to improve the treatment of CCOC.

Report this publication

Statistics

Seen <100 times